Treatment With Grazoprevir/Elbasvir for Renal Transplant Recipients With Chronic Hepatitis C Virus Infection and Impaired Allograft Function.

Journal: Transplantation direct
Published Date: Dec 27, 2018

Abstract

BACKGROUND: Direct-acing antiviral agents are highly efficient treatment options for chronic hepatitis C virus (HCV) infection after renal allograft transplantation. Treatment options for patients with impaired graft function remain limited. Therefore, we assessed the effectiveness and safety of grazoprevir/elbasvir therapy for patients with chronic HCV infection and impaired renal allograft function.

Authors

  • Ute Eisenberger
    Department of Nephrology, University Hospital Essen, University of Duisburg-Essen, Duisburg, Germany.
  • Justa Friebus-Kardash
    Department of Nephrology, University Hospital Essen, University of Duisburg-Essen, Duisburg, Germany.
  • Hana Guberina
    Department of Infectious Diseases, University Hospital Essen, University of Duisburg-Essen, Duisburg, Germany.
  • Andreas Kribben
    Department of Nephrology, University Hospital Essen, University of Duisburg-Essen, Duisburg, Germany.
  • Oliver Witzke
    Department of Infectious Diseases, University Hospital Essen, University of Duisburg-Essen, Duisburg, Germany.
  • Katharina Willuweit
    Department of Gastroenterology and Hepatology, University Hospital Essen, University of Duisburg-Essen, Duisburg, Germany.
  • Guido Gerken
    Department of Gastroenterology and Hepatology, University Hospital Essen, University of Duisburg-Essen, Duisburg, Germany.
  • Kerstin Herzer
    Department of Gastroenterology and Hepatology, University Hospital Essen, University of Duisburg-Essen, Duisburg, Germany.

Keywords

No keywords available for this article.

External Resources

Popular Topics
Recent Journals